Radioligand Therapy Market To Grow From USD 2.98 Billion In 2025 To USD 15.85 Billion By 2035, At A CAGR Of 18.2% - SNS Insider
Austin, United States, Sept. 07, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Radioligand Therapy Market was valued at USD 2.98 Billion in 2025 and is expected to reach USD 15.85 Billion by 2035, growing at a CAGR of 18.2% from 2026 to 2035. The demand is rising due to the increase in cases of prostate cancers and neuroendocrine tumors, the development of PS004DA and SSTR targeting agents, and survival advantages that have been achieved through certain drugs such as Pluvicto and Lutathera. In 2026, Pluvicto (177Lu-vipivotide tetraxetan) got FDA approval for a new indication in earlier-line metastatic castration-resistant prostate cancer, hence widening the pool of patients who can benefit from it and ensuring that PSMA targeted radioligand therapy becomes a standard treatment before chemo therapy.
Increased Lutetium-177 and Actinium-225 production, increased utilization of PSMA and SSTR PET imaging for patient selection, and increased research in radioligand therapy and immunotherapy are some of the factors improving precision oncology, all attributed to strategic acquisitions of radioligand developers by big pharmaceutical companies.
Download the Radioligand Therapy Market Sample Report:
Radioligand Therapy Market Key Highlights
- Market size, 2025: USD 2.98 Billion Market size, 2026E: USD 3.52 Billion Market forecast, 2035: USD 15.85 Billion CAGR: 18.2% from 2026 to 2035 Largest region: North America, approximately 80.50% share in 2025 Fastest-growing region: Asia Pacific, approximately 21.50% CAGR Largest product: Lutetium-177 Vipivotide Tetraxetan (Pluvicto), approximately 52.30% share in 2025 Fastest-growing product: Others (pipeline alpha-emitter agents), approximately 24.60% CAGR Largest indication: Prostate Cancer, approximately 58.40% share in 2025 Fastest-growing indication: Neuroendocrine Tumors, approximately 19.60% CAGR Largest target receptor: PSMA, approximately 61.20% share in 2025 Fastest-growing target receptor: Others (emerging targets), approximately 22.30% CAGR Largest end user: Hospitals & Specialized Cancer Centers, approximately 64.10% share in 2025 Fastest-growing end user: Diagnostic & Imaging Centers, approximately 20.90% CAGR
Market Relevance
Radioligand therapy has emerged as a promising precision oncology technique, which administers cytotoxic radioactivity selectively to tumor cells carrying a specific biomarker while avoiding normal cells. This modality provides an alternative treatment modality for patients resistant to conventional chemotherapy, hormonal treatments, and radiation therapy, further supporting the need for radiopharmaceuticals targeting PSMA and SSTR.
Radioligand Therapy Market Overview
The market comprises beta-emitting drugs, such as Pluvicto and Lutathera and a range of pipeline alpha-emitting drugs with Actinium-225 and Lead-212 at play that will be administered through hospitals, cancer care centers, and diagnostic centers. The PSMA targeted drug treatment still plays a vital role in the treatment of prostate cancer due to the high overexpression of the target in tumor cells, whereas the SSTR targeted drugs are for neuroendocrine tumors. Alpha emitters have greater linear energy transfer than beta emitters, but they penetrate shorter distances into the tissue.
Strategic Market Outlook
Areas of growth include innovation within the field of alpha-emitters and pipeline expansion in indications. The isotopes, actinium-225, and lead-212, demonstrate greater tumor killing capability via linear energy transfer compared to common beta emitters, and future research and development on breast, pancreatic, and lung cancers would likely boost patient accessibility. Increased investments from governments to develop nuclear medicine infrastructure in Asia-Pacific and Latin America regions are anticipated to generate more demand in these underpenetrated markets.
Limited availability of isotopes and special infrastructure requirements represent a significant limitation. Both lutetium-177 and actinium-225 are made using specialized reactors or cyclotrons available in just a few places, which creates supply risk, and limited half-lives of isotopes increase logistical challenges between production and administration facilities. Costly treatments and varying reimbursement options, especially in emerging economies that lack the infrastructure for nuclear medicine, create limitations for further market expansion.
Radioligand Therapy Market Regional Analysis
North America had 80.50% of the worldwide market share in 2025, as North America is the largest region owing to the presence of a strong infrastructure for theranostics, existing PSMA and SSTR PET imaging, and favorable reimbursement channels through Medicare and insurance. The United States has approximately 85.60% share in the North America market owing to the presence of its infrastructure for manufacturing radiopharmaceuticals and high prostate cancer rate, while Canada is developing infrastructure for nuclear medicine and radioisotopes production.
The U.S. Radioligand Therapy Market was valued at USD 2.04 Billion in 2025 and is projected to reach USD 10.68 Billion by 2035, growing at a CAGR of 18.00% from 2026 to 2035.
The Europe Radioligand Therapy Market was valued at USD 0.36 Billion in 2025 and is expected to reach USD 1.79 Billion by 2035, growing at a CAGR of 17.50% from 2026 to 2035. Germany accounted for approximately 24.30% of European revenue in 2025, supported by a strong academic research base and domestic radiopharmaceuticals industry, while France, Italy, and Spain are contributing through expanding theranostics trial networks and PET-CT/SPECT-CT infrastructure investment.
Asia-Pacific region remains the most rapidly developing, with a CAGR of around 21.50%. The market share held by Japan in the Asia-Pacific region was around 29.80% in 2025, which can be attributed to the early approval of regulatory authorities for PSMA radioligand therapies and better reimbursement policies for health insurance in the country.
Middle East & Africa: The UAE accounted for approximately 26.40% of regional revenue in 2025, with the UAE and Saudi Arabia investing in state-of-the-art nuclear medicine facilities that are gradually increasing radioligand therapy adoption.
Latin America: Brazil led regional revenue at approximately 39.20% in 2025, supported by growing academic oncology research capabilities and rising investment in specialized nuclear medicine treatment centers in major cities.
Buy the Radioligand Therapy Market Report with Competitive Analysis and 2035 Forecast:
Radioligand Therapy Market Segment Analysis
By Product: Lutetium-177 Vipivotide Tetraxetan (Pluvicto) had market share of about 52.30% in 2025 due to its being the first FDA approved radioligand therapy using PSMA for metastatic castration-resistant prostate cancer with survival advantage. The Others segment comprised of pipeline alpha emitter therapeutics using Actinium-225 and Lead-212 was growing the fastest with CAGR of 24.60%.
By Indication: The Prostate Cancer segment is estimated to hold 58.40% of the market in 2025 due to the prevalence of prostate cancer being the most frequent malignant disease among men across the world and the survival advantage offered by PSMA-based treatment. Neuroendocrine Tumors is the fastest-growing indication, with a growth rate of 19.60% CAGR.
By Target Receptor: The market share of PSMA was approximately 61.20%, due to its high overexpression on prostate cancer cell lines compared to normal tissues. The Other segment comprising gastrin-releasing peptide receptor (GRPR) and fibroblast activation protein (FAP) as targets is growing at the fastest CAGR of approximately 22.30%.
By End User: The Hospitals & Specialized Cancer Centers held a market share of about 64.10% in 2025 due to their contribution towards being a site for clinical trials and providing a specialized monitoring facility for patients. The Diagnostic & Imaging Centers is the fastest growing category with a CAGR of about 20.90%.
Radioligand Therapy Market Key Trends
- Rising adoption of PSMA-targeted alpha-emitter therapies accelerating the shift toward earlier-line, biomarker-driven prostate cancer treatment Expanding Lutetium-177 and Actinium-225 production capacity easing historical radioisotope supply constraints Growing use of PSMA and SSTR PET imaging for patient selection improving treatment precision Increasing strategic acquisitions of clinical-stage radioligand developers consolidating the competitive pipeline Expanding clinical exploration of radioligand combination regimens with immunotherapy
Competitive Landscape
The Radioligand Therapy Market includes established pharmaceutical leaders and specialized radiopharmaceutical developers, with competition centred on PSMA-targeted therapy expansion, alpha-emitter innovation, and isotope manufacturing capacity.
In 2026, Novartis received expanded U.S. FDA approval for Pluvicto in earlier-line metastatic castration-resistant prostate cancer, broadening its eligible patient population, and broke ground on a new radioligand manufacturing facility in Indiana to expand Lutetium-177 production. Eli Lilly and Company advanced 177Lu-PNT2002, its PSMA-targeted radioligand candidate, into a pivotal Phase 3 trial for biochemically recurrent prostate cancer. Bayer AG expanded U.S. manufacturing capacity for Xofigo (radium-223 dichloride) to strengthen supply for bone-metastatic castration-resistant prostate cancer patients.
Major key players include
- Novartis AG Eli Lilly and Company Bayer AG AstraZeneca plc Bristol-Myers Squibb Company Lantheus Holdings, Inc. Curium Pharma Telix Pharmaceuticals Limited ITM Isotope Technologies Munich SE Sanofi Orano Med RadioMedix, Inc. Clarity Pharmaceuticals Ariceum Therapeutics GmbH Perspective Therapeutics, Inc. Evergreen Theragnostics, Inc. Radiopharm Theranostics Limited Convergent Therapeutics, Inc. AdvanCell Pty Ltd. Molecular Partners AG
Explore the Complete Radioligand Therapy Market Report:
CONTACT: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315-961-9094 (US) Email:...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment